Andrew Turk, MD

Andrew Turk, MD, discusses the main factors that can be used to determine whether a patient presenting with thyroid cancer has an indolent form of the disease or a more aggressive thyroid cancer.

Andrew Turk, MD, discusses targeted agents that are making a splash in the treatment landscape of thyroid cancers, including the most aggressive form of the disease, anaplastic thyroid carcinoma. He says targeted agents have already become well established in the space of thyroid cancers, but these agents continue to evolve.

Andrew Turk, MD, discusses the importance of discussing thyroid cancer at major meetings, such as the 2019 ASCO Annual Meeting. It is important for physicians to keep up to date on the latest advancements for treatment options and new understandings of the disease and its subtypes.